Antihypertensive Indications Should Include Benefit On Cardiac Outcomes, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Most conclusive benefit seen from lowering blood pressure is reduction of stroke, Cardiovascular & Renal Drugs Advisory Committee says. Products that have cardiac outcomes studies could include data in labeling, committee adds.
You may also be interested in...
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
Antihypertensive Class Labeling Public Health Impact Assessment Being Considered By FDA
Class labeling for antihypertensives on blood pressure reduction and cardiovascular outcomes to be discussed during an April 26 meeting.